News Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant funding for the development of a Schizophrenia treatment. Monument was spun out of Cambrid ..read more

Insights 2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I got the news about receiving the CANTAB research grant secondary award. The support allows me to collect cognitive fun ..read more

News Cambridge Cognition strengthens senior management team to deliver growth Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior leadership team in pursuit of its ambitious growth strategy. Alex joins Cambridge Cognition with a wealth of sector experience, having worked in the clinical trial ..read more

Insights 2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minho​who. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am deeply grateful to Cambridge Cognition for awarding me the CANTAB Research Grant 2023 Sec ..read more

Insights Digital Biomarkers & Alzheimer’s Research: Q&A with Liam Kaufman, VP of Clinical Sciences Kaufman discusses the ways the digital biomarkers are improving Alzheimer’s research by directly tackling some of the unique challenges that researchers face. by Mike Hollan Originally published on PharmExec.com Researching and developing treatments for Alzheimer’s disease comes with unique challenges, due to the nature of the disease. Liam Kaufman, VP of clinical sciences at Cambridge Cognition, spoke with Pharmaceutical Executive about how digital biomarkers are being used ..read more

News Cambridge Cognition and ActiGraph announce partnership to accelerate central nervous system trials by ActiGraph PENSACOLA, FL, February 20, 2024 – ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20 pharma companies in clinical trials already. Cambridge Cognition has joined ActiGraph’s Accelerant par ..read more

News Cambridge Cognition announces scientific advisory board Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers and the collaborative possibilities for computerised cognitive assessments. The SAB combines expertise covering CNS-related disorders, clinical development, and academia w ..read more

eBooks & Whitepapers, Publications & posters Digital measures to advance research & quality of life in schizophrenia Schizophrenia spectrum disorders are complex and serious psychiatric disorders. In addition to prominent psychiatric symptoms such as hallucinations, delusions, and negative symptoms (e.g., loss of motivation), schizophrenia is associated with functional impairment in major life areas (e.g., occupational and interpersonal functioning). This functional impairment has been linked not only to the psychiatric symptoms noted above, but also to associated deficits i ..read more

News Back to resource centre 20 September 2023 Cambridge Cognition's Global Teams Unite for Mental Health Causes! Last weekend marked the annual charity challenge here at Cambridge cognition, teams from the UK and Canada came together for two challenging fundraising events. Our UK team conquered the 47-mile Norfolk Coastal Path in less than 24 hours, raising funds for  Sport in Mind, while our Canadian team completed a 12 km walk/run for the Alzheimer Society of Toronto.  Engaging in charity challenges provides us with the opportunity to both personally and directly make a diffe ..read more

Insights, Technology for successful decentralised clinical trials The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality.  At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog post, we’ll delve into the world of DCTs, exploring their benefits, challenges, and the role of technology in driving this paradigm shift ..read more